




President Annual Activity Report for 2022

Anna Sureda, EBMT President


Science

Scientific productivity


Impact Factor




Publications



Oral presentations



Poster presentations



The Registry Upgrade Project

- Since 2022, the EBMT together with National Registries have worked to develop the new tool that will take ProMISe's place: the EBMT Registry, its first version will be with some limitation in its functionalities.
- The content within the data collection forms have been revised.
- A new data model has been adopted called OMOP-CDM, which will facilitate in the future fruitful collaboration with other Registries.
- EuroTraCTOR (European Transplant and Cellular Therapy Online Registry), an EU grant funded under the EU4Health programme: the project started at the end of 2022 and it aims at designing, launching and assuring the future sustainability of the new EBMT Registry. EBMT is the main beneficiary and a coordinating entity.

CAR-T Data Collection Initiative (1)

EBMT has actively encouraged centres to report data on patients treated with CAR T-cell therapies to support Post Authorisation Safety (PAS) studies mandated by the EMA.

EBMT has focused on the performance of 5 PAS studies where EBMT is responsible for the data collection in these PAS studies performed by the Marketing Authorisation Holders:


1. Kymriah (Tisagenlecleucel) by Novartis, approved for ALL and DLBCL
2. Yescarta (Axicabtagene ciloleucel) by Kite-Gilead, approved for DLBCL and PMBCL (FL will follow)
3. Tecartus (Brexucabtagene autoleucel) by Kite-Gilead, approved for MCL (ALL fill follow) (Research agreement expected to be signed Q4 2022)
4. Abecma (Idecabtagene vicleucel, ide-cel) by BMS-Celgene, approved for MM
5. Breyanzi (Lisocabtagene maraleucel, liso cel) BMS-Celgene, approved for DLBCL, PMBCL and FL.

CAR-T Data Collection Initiative (2)

Castor EDC, the database for cellular therapy, holds 4,600 CAR T-cell patients (see below).

The Data collection handbook for Castor EDC was created in 2022 together with the Cellular Therapy Forms Manual.


The graph below illustrates the steady growth of new reported cases into the EBMT Registry since 2019 and the reflected number of centres.



Source: EBMT Registry, January 2023

*Patients identified and marked with a CAR T-cell treatment, having at least minimal data on the diagnosis and treatment.

The map below represents a geographical approach in blue of all our reporting countries who are continually submitting data to the EBMT Registry.



Source: EBMT Registry, January 2023

Education

48th Annual Meeting of the EBMT

In [March](#) 2022, the Prague Congress Centre closed its doors to hosting the EBMT Congress in order to use it to support refugees from Ukraine. As a consequence, the 48th Annual Meeting of the EBMT was organised as a fully Virtual Meeting instead of the Hybrid format, as was initially planned.

The Annual Meeting was a success with [5,005 registered attendees](#) from 90 countries.



Educational events 2022

- **January:** 3 virtual Working Party meetings held by the CTIWP, CMWP, and SAAWP.
- **February:** EBMT-EHA 4th European CAR T-cell Meeting [virtual]
- **March:** 48th Annual Meeting of the EBMT [virtual]
- **May:** Joint ASTCT-EBMT Basic and Translational Scientific Retreat – Colorado, USA
- **September:** 7th International Transplant Course – Barcelona, Spain
- **September - November:** 7 in-person across Europe and 1 virtual educational meetings:
 1. ADWP Educational Meeting - London, UK
 2. IEWP Annual Conference - Paris, France
 3. TCWP Educational Meeting - Berlin, Germany
 4. CMWP Educational Meeting - Milan, Italy
 5. Nurses Group Study Days - Brussels, Belgium
 6. IDWP Educational Course - Florence, Italy
 7. PDW Educational Meeting - Regensburg, Germany
 8. LWP Educational Course - Virtual
- **November:**
 - 2nd EBMT-China Scientific Forum – Hybrid, Tianjin, China
 - JACIE Training Course – Castelldefels, Spain



E-learning

- Over the course of 2022, EBMT's e-learning project has also grown and matured. There are many resources available in the platform for continuous online education: **E-courses, forums, and webinars.**
- The E-Learning Unit organised **32 webinars** in 2022. There were **Physician** webinars, **Paediatric** webinars, **JACIE Inspectors** webinars, and **GoCART** webinars that included clinical discussions for Physicians and best practice discussions for Nurses. More details [here](#)
- The **Chimera e-course series**, a project lead by the EBMT's **Trainee Committee** that aims to cover all aspects surrounding HCT and cellular therapy with a focus on trainee-relevant knowledge and skills, was launched during the end of 2021, and many modules were added in 2022.

The image displays the EBMT e-learning platform interface. At the top, there is a navigation bar with the EBMT logo, a search bar, and links for 'User Login' and a shopping cart icon. Below the navigation bar, there are four course cards:

- Castor EDC fundamentals**: This course contains an explanation of the new e-learning platform tool for Cellular Therapy Data. It consists of videos and a quiz. After completion, you will be certified to obtain access to Castor. **If you are not a member, you must fill in this form.**
- Chimera**: This course contains trainee-relevant knowledge and skills on hematopoietic cell transplantation and cellular therapy brought to you by The EBMT Trainee Committee. This course is divided into several modules that include short presentations and quizzes. **If you are not a member, you must fill in this form.**
- EBMT Benchmarking Webinar**: This course contains a webinar explaining the origins and methodology of the EBMT Clinical Outcomes Group (COG) benchmarking model for one-year survival following allogeneic and autologous HSCT.
- EBMT Online Learning Course for Nurses**: This course is an e-learning program adapted from the EBMT Handbook for Nurses, for nurses with an interest in Hematopoietic Cell Transplantation. It includes content from the textbook and quizzes. **If you are not a member, please fill in this form to register for the e-learning platform and access this course.**

Below the course cards, there is a video player for the 'Chimera' e-learning platform. The video player shows a large, stylized illustration of a chimera (a creature with a human head and a multi-limbed body) against a red background. The text on the video player reads: 'Welcome to Chimera! - an EBMT e-learning platform from trainees for trainees', 'EBMT', 'Chimera an e-learning platform from trainees for trainees', and 'e-learning'. There are also buttons for 'Watch Later', 'Share', and 'Watch on YouTube'.

Advocacy & Quality of Care

JACIE – Accreditation in 2022


63 APPLICATIONS in 2022

The number of applications has remained relatively stable with the exception of 2020 with lower than average number of applications due to Covid -19 pandemic.

64 INSPECTIONS in 2022

2022 marked a return to nearly post-pandemic levels of inspection activity using all inspection modalities available ('short process', 'remote' and onsite inspections).

In total, **64 inspections** were carried out in 2022 and **26 centres achieved JACIE accreditation**.



JACIE – Benchmarking

The FACT-JACIE Standards require centres to review their clinical outcomes against wider datasets, referred to as benchmarking. EBMT as a registry holder is in a unique position to offer an international benchmarking scheme to centres that report data.

The centres participating in the project received their report in September 2022.

A further manuscript on Benchmarking Project was submitted at the end of 2022 and published in March 2023.

Bone Marrow Transplantation

Explore content ▾ About the journal ▾ Publish with us ▾

[nature](#) > [bone marrow transplantation](#) > [articles](#) > article

Article | [Open Access](#) | [Published: 09 March 2023](#)


Benchmarking of survival outcomes following Haematopoietic Stem Cell Transplantation (HSCT): an update of the ongoing project of the European Society for Blood and Marrow Transplantation (EBMT) and Joint Accreditation Committee of ISCT and EBMT (JACIE)

[Riccardo Saccardi](#)  [Hein Putter](#), [Dirk-Jan Eikema](#), [María Paula Busto](#), [Eoin McGrath](#), [Bas Middelkoop](#), [Gillian Adams](#), [Marina Atlija](#), [Francis Ayuketang Ayuk](#), [Helen Baldomero](#), [Yves Beguin](#), [Rafael de la Cámara](#), [Ángel Cedillo](#), [Anna María Sureda Balari](#), [Christian Chabannon](#), [Selim Corbacioglu](#), [Harry Dolstra](#), [Rafael F. Duarte](#), [Rémy Dulery](#), [Raffaella Greco](#), [Andreu Gusi](#), [Nada Hamad](#), [Michelle Kenyon](#), [Nicolaus Kröger](#), ...

[John A. Snowden](#) [+ Show authors](#)

Nurses Group Activities in 2022

- Content revision and chapter development for the [2nd edition of the EBMT Textbook for Nurses](#) to be launched at the 49th Annual Meeting of the EBMT in Paris, April 2023. It will be the 1st of the NG publications to be fully translated and will be available in French among other languages.
- In October 2022 the [EBMT Nurses Group Immune Effector Cell \(IEC\) Forum](#) was launched. It is designed for nurses and AHPS looking after patients receiving Immune effector cells such as CAR-T therapy, anywhere in the patient pathway.
- The GoCART Coalition and the EBMT Nurses Group launched a [webinar series on CAR-T therapies](#).
- [5 publications](#) in peer reviewed journals.





GoCART
COALITION

Multi-stakeholder coalition collaborating to maximise the potential of cellular therapies manufactured from cells and tissues of hematopoietic origin.

- The GoCART Coalition continued to work actively in 2022 in the **six Work Packages:**
 1. Data Harmonisation
 2. Standards of Care
 3. HTA
 4. Education
 5. Policy and Advocacy
 6. Scientific Excellence



Call for Research Proposals 2022 and announcement of the three winning proposals

- EBMT and EHA released the **2nd call for retrospective research proposals** within the WP6, in August 2022. Out of the 16 scientific projects that were presented, 3 of them were selected by the selection committee:
 1. “Impact of preceding therapy on the feasibility, safety and efficacy of anti-CD19 CAR-T cells in acute lymphoblastic leukemia” (co-PIs: Valentín Ortiz-Maldonado and Sebastian Giebel)
 2. “Efficacy and toxicity of CAR T cell therapy in patients with primary and secondary central nervous system lymphoma. A Retrospective Analysis of the Lymphoma WP of the EBMT” (PI: Anna Laube)
 3. “Infections following CAR-T therapy. A retrospective collaborative study between the IDWP, CTIWP, TCWP of the EBMT, the European Hematology Association (EHA), and the Medical College of Wisconsin” (PI: Dina Averbuch)
- The 16 proposals were evaluated against four criteria: *scientific impact, novelty, collaboration across stakeholders* and *feasibility of the proposal*.
- The selection committee was composed by Anna Sureda (President of the EBMT), Christian Chabannon (Past Chair EBMT CTIWP), John Gribben (Past President of the EHA), Martin Dreyling (Board Member of EHA) and Natacha Bolaños (Chair EBMT Patient Advocacy Committee).

Other key achievements in 2022

2022 Working Party elections



EBMT Acute Leukaemia Working Party Chair - Fabio Ciceri



EBMT Chronic Malignancies Working Party Chair - Donal McLornan



EBMT Cellular Therapy & Immunobiology Working Party Chair - Annalisa Ruggeri

New Haemoglobinopathies Working Party

- The establishment of the new [Haemoglobinopathies Working Party](#) was approved by the Board in October 2022.
- Two nominated candidates were Board of Association-approved at the EBMT Board Meeting 26-27 January 2023 in Paris:
 - Josu de la Fuente - Professor of Practice (Cellular & Gene Therapy) and Consultant Haematologist, Imperial College London, UK
 - Emanuele Angelucci - Transplant Program Director, San Martino Polyclinic Hospital, Genoa, Italy
- Voting for EBMT Elections opens on 11 April 2023 and the results will be announced at the General Assembly Meeting on 25 April 2023

New Practice Harmonisation Committee

- The new [Practice Harmonisation Committee](#) terms of reference were approved by the Board of Association and Scientific Council at the EBMT Board Meeting 26-27 January 2023 in Paris.
- This committee will be led by Ibrahim Yakhoub-Agha, ex-board member and CMWP Chair, and will take on the following tasks:
 - Draft a method of practice harmonisation (PH) and guidelines (G)
 - Liaise with WP chairs to select subjects of PH&G and to select potential experts
 - Track practice changes and update them as needed
 - Contribute to the strategic direction of the EBMT, including the definition of guidelines, policies and procedures as necessary
 - Liaise with Corporate Patrons and other sponsors to provide scientific input and encourage financial support activities beneficial to the EBMT

Publications by the EDI and the Trainee Committee

- The [Equality, Diversity and Inclusion \(EDI\) Committee](#), published its first paper in *Bone Marrow Transplantation*: “The first steps towards a diverse and inclusive EBMT: a position paper” and a 4-year report on the achievements and challenges on EDI.
- The [Trainee Committee](#) published a paper in the *Lancet Haematology*: “Recognising inequalities in haematopoietic stem-cell transplantation and cellular therapy training”.

Ukrainian Crisis Assistance Program

- In response to the Russian invasion of Ukraine and the devastating impact it had on civilians and patients in the affected regions, EBMT immediately set up an initiative called the [EBMT Ukrainian Crisis Assistance Program \(UCAP\)](#).
- This program has been continuously active throughout 2022 and has constructed a discussion forum of potential candidates for cellular therapy strategies.

Thank you!






EBMT Secretary's Annual Activity & Membership Report for 2022

John Snowden, EBMT Secretary

Membership Overview

EBMT Members



Source: Promise January 2023

Centre Members

CENTRES - Membership Overview

Global Figures

	GAM2023	GAM 2022	GAM 2021
Number of EBMT CENTRES	647	620	579
Of which PROVISIONAL centres	18	35	9
Of which have been REACTIVATED	18	17	4
Of which FULL centres	579	534	512
Of which ASSOCIATE centres	50	51	58

Source: Promise January 2023

CENTRES - Membership Overview

Global Figures 2022

Position	Country	Number of centres GAM 2023	Number of centres GAM 2022	Number of centres GAM 2021
1	Germany	92	90	89
2	Italy	88	85	79
3	France	64	58	48
4	UK	53	53	51
5	Spain	50	48	47
6	Turkey	39	38	39
7	China	22	22	4
8	Poland	21	21	17
9	Belgium	14	15	15
10	Netherlands	15	15	15

The **647** EBMT centres are located in **58** countries

The **top 10** split of Centres represents **458** Centres (70'08% of total)

CENTRES - Membership Overview

New Provisional Centres

The following 18 provisional new centres are pending approval from the GA

CIC	Institution	Country
1034	Gemelli Molise	Italy
1035	N.N. Blokhin National Medical Research Center of Oncology Adult	Russia
1036	Akbar Niazi Teaching Hospital	Pakistan
1037	Hospital Universitario Miguel Servet	Spain
1038	Haemlife	South Africa
1039	Ospedale Nuovo di Legnano	Italy
1040	Centre Hospitalier Henri Duffaut	France
1041	NBK Children's Specialized Hospital	Kuwait
1042	Clínica Imbanaco - Unidad de Trasplante de Médula Ósea	Colombia
1043	Hospital Universitario Príncipe de Asturias	Spain
1044	Franziskus-Hospital Harderberg	Germany
1045	Hospital Nove de Julho	Brazil
1046	Özel Kori Ankara Hastanesi	Turkey
1047	The Children Hospital and University of Child H. S. Lahore	Pakistan
1048	Centre Hospitalier de Luxembourg	Luxembourg
1049	Warszawski Uniwersytet Medyczny	Poland
1050	Clínica Dávila	Chile
1051	Clinica Santa Maria	Chile

Individual Members

Individual Membership Overview

Global Figures

	GAM2023	GAM 2022	GAM 2021
Number of INDIVIDUAL members	241	163	144
<i>Of which PROVISIONAL individuals</i>	49	44	38
<i>Physicians</i>	185	146	100
<i>Nurses</i>	36	38	38
<i>Other</i>	14	12	3
<i>Patient Representative</i>	2	3	2
Honorary members	36	36	30

Source: Promise January 2022

Individual Membership Overview

New Individual Members 2022

The following 49 Provisional Individual Members pending approval from GA (slides 9-11)

CIC	Full name	Role	Country
10891	Madiha Iqbal	Physician	United States of America
10892	Mohammad Mostafil Karim	Physician	Bangladesh
10893	Olivier Veilleux	Physician	Canada
10897	Semih Basci	Physician	Turkey
10902	Merih Kizil Cakar	Physician	Turkey
10903	Bahar Uncu Ulu	Physician	Turkey
10904	Daniel Ernst	Physician	Chile
10905	Sudeep Vaniyath	Physician	India
10906	Candice Hendricks	Physician	South Africa
10907	Sabrina Giammarco	Physician	Italy
10909	Priti Mehta	Physician	India
10910	Pashna Munshi	Physician	United States Of America
10911	Andrea Acerbis	Student/PhD Student	Italy
10912	Giorgio Orofino	Student/PhD Student	Italy
10913	Parinda Mehta	Physician	United States
10914	Alexandros Rampotas	Student/PhD Student	United Kingdom
10915	R. Alejandro Sica	Physician	United States
10916	Munira Borhany	Physician	Pakistan
10917	Sanjeet Dadwal	Physician	United States
10918	Ranjit Kumar Chatada Srivaishnava	Physician	United States
10919	Mehmet Ali Uçar	Physician	United States
10920	Sadaf Altaf	Physician	Pakistan

Individual Membership Overview

New individuals 2022

CIC	Full name	Role	Country
10921	Mohamed Elbogdady	Physician	Egypt
10922	Virginia Abello-Polo	Physician	Colombia
10923	Deepesh Lad	Physician	India
10924	Barnali Srivastava	Physician	Australia
10925	Jayachandran Perumal Kalaiyarasi	Physician	India
10926	Nayera Abdelhafez	Physician	Egypt
10927	Olha Dashchakovska	Physician	Ukraine
10928	Vipul Sheth	Physician	United States
10929	Thomas Wainwright	Lab Technician	United Kingdom
10930	Pamela Dennis Montenegro Chahar	Physician	Bolivia
10931	Farrukh Ali Khan	Physician	Pakistan
10932	Simona Calza	Nurse	Italy
10933	Satu Kauppinen	Nurse	Finland
10934	Gaurav Srivastava	Physician	Australia
10935	Hannah Lust	Physician	United States
10936	Nida Anwar	Physician	Pakistan
10937	Mussawair Hussain	Physician	Pakistan
10938	Fatma Ebeid	Physician	Egypt
10939	Nancy Eunice Torres	Physician	United States
10940	Paramveer Singh	Student/PhD Student	United States
10941	Ahmed Saad	Physician	Egypt

Individual Membership Overview

New individuals 2022

CIC	Full name		Role	Country
10942	Genovefa Papanicolaou		Physician	United States
10943	Mohammad Biglari		Physician	Iran
10944	Maryam Bagherian		Physician	Iran
10945	Adriana Seber		Physician	Brazil
10946	Muhammad Arshad		Physician	Pakistan
10947	Mehndi Dandwani		Physician	United States

Full Centre Membership to Associate

Full Centre Membership to Associate

50 full member centres have been unable to report all data in 2022.

Normally, these centres would be downgraded to associate membership, however, due to the upgrading of EBMT's registry this has not been possible in 2022. Downgrading will therefore be postponed to 2024 to provide sufficient time for centres to catch up with all reported data.

Thank you!





Treasurer's Annual Financial Report for 2022

Harry Dolstra, EBMT Treasurer

Final 2022 numbers for voting

Financial highlights

	2022			2022	
	EUR	%		EUR	%
Source of Income			Destination of resources		
EBMT Members donations	704,000	5.6%	Scientific Studies	3,323,000	29.5%
Scientific Sponsors donations	598,000	4.7%	EBMT Registry	2,245,000	19.9%
Annual Meeting	4,756,000	37.5%	Annual Meeting	1,052,000	9.3%
Results from investments	- 229,000	-1.8%	Educational Activities	1,911,000	16.9%
			Standards & Accreditation (JACIE)	953,000	8.5%
Non-earmarked Income	5,829,000	46.0%	Total Mission Cost	9,484,000	84.1%
Grants for Studies, Clinical Trials & Education	6,099,000	48.1%	Management and Administration	1,792,000	15.9%
Accreditation (JACIE)	754,000	5.9%			
Earmarked Income	6,853,000	54.0%	Total Expenditure	11,276,000	100.0%
Total Income	12,682,000	100.0%			

Position of EBMT - rating

Program %	Cost to Raise \$100	Efficiency Rating	
90-100%	\$0 - 4	A+	
80 - 89%	\$5 - 11	A	Current position EBMT
75 - 79%	\$12 - 15	A-	
72 - 74%	\$16 - 19	B+	
68 - 71%	\$20 - 26	B	
65 - 67%	\$27 - 30	B-	
61 - 64%	\$31 - 33	C+	
56 - 60%	\$34 - 37	C	
50 - 55%	\$38 - 40	C-	
36 - 49%	\$41 - 59	D	
0 - 35%	\$60 - 100	F	

Source: <https://www.charitywatch.org/charitywatch-criteria-methodology>

Final 2022 numbers for voting

Financial outcome	2022	
	EUR	%
Total Income	12,682,000	100.0%
Total Costs	11,276,000	88.9%
Gross Result	1,406,000	11.1%
Earmarked	- 437,000	-3.4%
Net result	1,843,000	14.5%



Final Conclusions

The ongoing positive financial development of the organisation over the past years has allowed EBMT to further build on its strategic goals and improve its organisational structure.

Current highlights include the successful virtual and face-to-face educational and scientific meetings, increasing E-learning opportunities, registry upgrade, cellular therapy registry, benchmarking system, CART PASS studies, staff compensation and human resource management, information technology innovation and building the Science Fund.

In spite of the financial challenges, EBMT will be closing the year 2022 with a positive total result of EUR 1,406,000 (expenses of EUR 11,276,000 and a total income of EUR 12,682,000) thanks to the fantastic work of the EBMT staff, community and the use of our financial reserves.

Income and human resources evolution



Spending our financial resources on our missions

Our steady annual income has been used to strengthen our growing organisation.

For 2022, the budget needed for management and administration (i.e., Board and Executive Office expenses) decreased to 15.9% which allocates 84.1% to our scientific studies, registry, accreditation and education like the 2022 Annual Meeting, E-learning and educational events.

Therefore, EBMT remains a very efficient organisation when assessed by international rankings (“A” according to CharityWatch).



Continuing with a balanced financial strategy

In 2022, we continued to secure, improve and increase our staff positions while further optimizing EBMT organizations through a well-balanced financial roadmap for the future of EBMT.

Our goal was to be able to cover all financial challenges and strategic projects in line with our ambitions but also provide a strong backbone for the organization. The EBMT Board decided to partially release allocated reserves in 2022 (€437,000) to support our organization for the next years which covers the following topics and areas.



1) *Returning to face-to-face meetings*

The provision was that after fading of the COVID-19 pandemic we organized the EBMT annual meeting 2022 as a hybrid face-to-face and virtual meeting. But due to the war in Ukraine we needed to swiftly change for the third time our annual congress to a virtual meeting. Thanks to the great work and dedication of the Barcelona office the 2022 virtual annual meeting was a great success because we were able to maintain the high level of education, the support of our sponsors and the engagement of our delegates.

The completed in-housing operations of successive EBMT educational events strengthens the EBMT's educational positioning and visibility within the virtual arena and by having financial control. Nevertheless, many other EBMT meetings were returning with success to face-to-face meetings such as the International Transplant Course in September 2022 and Working party events.

Furthermore, the first face-to-face basic and translational science meeting jointly organized by ASTCT and EBMT in May 2022 in Vail Colorado was a great success.



2) Adapting the organisational structure

In 2022, we further adapted the managerial infrastructure of the EBMT which is structured in six departments Registry, Clinical Research, Education & Events, Advocacy & Quality of Care, Sales & Development and Support. Each department is led by a department Director whom, together with the Executive Director and Medical Officer, form the EBMT Management Team.

In 2022 we continued with improving the Clinical Research, Sales and Support departments in order to increase and streamline the process of setting up memberships, sponsorships, retrospective and prospective studies in collaboration with pharma, institutions and non-profit organizations as well as marketing & communications. The sponsorships and funded studies are a growing segment of the activities of EBMT and important financial pillar for our strategic mission.

Furthermore, the EBMT is increasingly recognized as partner in European projects such as the Egalite and EuroTractor project.

Due to the solid financial situation of EBMT, we were able to sustain all staff positions and finance the new, key positions within the transformed EBMT organizational structure. Further streamlining and restructuring the organigram will continue in 2023 in order to increase the efficiency of EBMT.



3) The science fund

In my term as Treasurer, we have developed the EBMT Science Fund and the EBMT Board decided to strategically allocate reserves in this fund to support strategic scientific studies with high priority for the mission goals of EBMT.

The first strategic topic included the COVID task force formed to support patients and the EBMT community during the COVID-19 pandemic. All working parties were involved in the COVID task force which was very productive in developing general and vaccination guidelines for patients, donors and the EBMT community, scientific surveys and Covid-19 related scientific studies.

In 2022, the EBMT Board decided to support the GoCART studies from the Science fund to financially support the winning CART studies after scientific evaluation within the GoCART coalition.

Furthermore, a CART task force has been formed lead by our Medical Officer and all working parties involved. In the next years we will continue to allocate reserves in the Science Fund to support strategic scientific top-priority projects.



4) Continuing the CAR T PASS studies

After receiving the qualification opinion from EMA regarding the cellular therapy module of the EBMT Registry, the Board decided to raise manpower to support this initiative, which will collect post-market evidence for safety and efficacy of different commercial CART products.

Contracts with three big pharma companies have been signed and more companies are likely to follow. The finance support behind these contracts allows for more man-hours to execute these PASS studies and increase the Registry data plus data quality. This registry tool will be helpful for all researchers executing clinical studies with immune effector cells to gather more comprehensive data sets.



5) Updating the EBMT REGISTRY

In 2022, we kept working on building the future Registry into a new IT system while continuing to enter transplant and cellular therapy data in ProMISe, and the CASTOR database to enter CART data for the EBMT and PASS scientific studies.

Building of the future Registry platform has the highest financial priority. Reserves have been earmarked to cover all expected costs. In addition, reserves are being used and held for any unexpected expenses.

Furthermore, all EBMT offices were and are still closely working together on this project under the supervision of the Executive Director and the CRD Department.



6) JACIE returning to live inspections

JACIE, after the pandemic, had clear challenges to resolve. However, I have already seen a high level of enthusiasm and commitment of everyone involved to find solutions to these challenges and current processes. Their work does not go unnoticed. The JACIE team completed 68 full inspections out of the 80 initially expected.

Moving forward, the second EBMT benchmarking exercise has paved the way for a second manuscript still pending to be published. Yet, the feasibility, acceptability and reliability of the system has been supported and the limitations have been identified. I cannot wait to see the impact JACIE and its team will have in 2023.



AUDITING PROCESS



At the time of preparation of this presentation (27 March 2023), the audit process was pending finalization.

During the closing meeting, the auditors indicated that they are going to provide an “unqualified opinion”.

Through the last years, EBMT obtained unqualified opinions, which demonstrates that the EBMT is maintaining its high standard of modern management, sustaining its financial stability and provides assurance that money is spent and allocated according to our mission.

The outcome of the Auditor’s Management Letter will be presented in one of the next Board meetings.



THANKS GO TO:



Andreu Gusi



Bas Natkiel



Liesbeth Hoekstra



Erwin Timmers



Sudy Anne Pourier

Finance Committee 2022 - 2025



Jurgen Kuball



Rafael Duarte

Thank you!





EBMT 2023 ELECTION RESULTS

John Snowden, EBMT Secretary



All eligible to vote Principal Investigators from EBMT full membership centres were invited to vote online for the following:

- EBMT Treasurer
- EBMT Severe Aplastic Anaemia Working Party Chair
- EBMT Paediatric Diseases Working Party Chair
- EBMT Haemoglobinopathies Working Party Chair
- EBMT 2023-2026 Strategic Plan
- EBMT Bylaw Amendments (articles 5 and 6)
- Executive Committee's Annual Reports for 2022

Voting took place online from the 11th April, 10h00 CET until Monday 24th April, 20h00 CET

192 ballots submitted of 579 eligible voters = 33% participation.

EBMT Treasurer - Mette D. Hazenberg PLURALITY

Yes - I approve the candidate

170 votes 97.14%

No - I reject the candidate

5 votes 2.86%

Yes - I approve the candidate wins with 97.14% of the vote.

175 votes tallied and 17 abstentions



Congratulations to Mette Hazenberg
EBMT Treasurer and Executive Committee Member

EBMT Severe Aplastic Anaemia Working Party Chair - Antonio Risitano PLURALITY

Yes - I approve the candidate

172 votes 96.09%

No - I reject the candidate

7 votes 3.91%

Yes - I approve the candidate wins with 96.09% of the vote.

179 votes tallied and 13 abstentions



Congratulations to Antonio Risitano
EBMT Severe Aplastic Anaemia Working Party Chair

EBMT Paediatric Diseases Working Party Chair PLURALITY

Petr Sedlacek

68 votes 48.57%

Krzysztof Kalwak

72 votes 51.43%

Krzysztof Kalwak wins with 51.43% of the vote.

140 votes tallied and 52 abstentions



Congratulations to **Krzysztof Kalwak**
EBMT Paediatric Diseases Working Party Chair

Haemaglobinopathies Working Party Chair PLURALITY

Josu de la Fuente

72 votes 43.90%

Emmanuele Angelucci

92 votes 56.10%

Emmanuele Angelucci wins with 56.10% of the vote.

164 votes tallied and 28 abstentions



Congratulations to Emanuele Angelucci
EBMT Haemoglobinopathies Working Party Chair

EBMT's Strategic Plan for 2023-2026 PLURALITY

Yes - I approve the Strategic Plan for 2023-2026

180 votes 97.83%

No - I reject the Strategic Plan for 2023-2026

4 votes 2.17%

Yes - I approve the Strategic Plan for 2023-2026 wins with 97.83% of the vote.

184 votes tallied and 8 abstentions

Bylaw Amendment Approval of Articles 5 and 6 PLURALITY

Yes - I approve the amendments

176 votes 96.70%

No - I reject the amendments

6 votes 3.30%

Yes - I approve the amendments wins with 96.70% of the vote.

182 votes tallied and 10 abstentions

EBMT President's Activity Report 2022 PLURALITY

Yes - I approve the President's Activity Report 2022 **185 votes 99.46%**

No - I reject the President's Activity Report 2022 **1 vote 0.54%**

Yes - I approve the President's Activity Report 2022 wins with 99.46% of the vote.

186 votes tallied and 6 abstentions

EBMT Treasurer's Annual Report for 2022 PLURALITY

Yes - I approve the Treasurer's Annual Report for 2022 **176 votes 98.32%**

No - I reject the Treasurer's Annual Report for 2022 **3 votes 1.68%**

Yes - I approve the Treasurer's Annual Report for 2022 wins with 98.32% of the vote.

179 votes tallied and 13 abstentions

EBMT Secretary's Annual Report for 2022 PLURALITY

Yes - I approve the Secretary's Annual Report for 2022 **175 votes 98.31%**

No - I reject the Secretary's Annual Report for 2022 **3 votes 1.69%**

Yes - I approve the Secretary's Annual Report for 2022 wins with 98.31% of the vote.

178 votes tallied and 14 abstentions



OUTGOING EBMT BOARD MEMBERS

Anna Sureda, EBMT President

We would like to take this opportunity to thank the following outgoing board members for their support and commitment to the Scientific Council and Board of Association during their mandate.



Harry Dolstra

EBMT Treasurer, member of the EBMT Executive Committee and member of the Board of Association 2019-2023



Régis Peffault de la Tour

EBMT Severe Aplastic Anaemia Working Party Chair from 2019-2023

Co-Chair of the EBMT Scientific Council with the Research and Sciences Portfolio and member of the Board of Association from 2021-2023



Selim Corbacioglu

EBMT Paediatric Diseases Working Party Chair from 2019-2023

Chair of the EBMT Scientific Council with the Research and Sciences Portfolio and
member of the Board of Association from 2019-2023

Special thanks also to....



Andreu Gusi Puig

EBMT Executive Director from 2009-2023

And welcome to...



Mirjam Steinbuch

EBMT Executive Director from 02/05/2023